---
schema_version: "secwatch.filing_event.v1"
accession: "0000784199-24-000234"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:07:09.916610+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Artivion Q3 revenue $95.8M (+9% YoY); EBITDA $17.7M (+28%); guides FY $389-396M

## Summary
- Revenue $95.8M (+9% GAAP, +10% constant currency); net loss ($2.3M) ($0.05 EPS) vs ($9.8M) ($0.24) prior year.
- Non-GAAP net income $5.0M ($0.12 EPS) vs $0.7M ($0.02); includes $2.4M foreign currency gains.
- Adjusted EBITDA $17.7M (+28%); FY guidance narrowed to $389-396M revenue and $69-72M EBITDA.
- On-X +15%, BioGlue +14%, stent grafts +12%; APAC +23% and LatAm +21% (constant currency +32%).
- Regulatory milestones: AMDS PMA module submitted, BioGlue approved in China, NEXUS TRIOMPHE enrollment complete.

## SEC filing metadata
- accession: 0000784199-24-000234
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000078419924000234/0000784199-24-000234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000078419924000234/aort-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000784199-24-000234
- JSON: https://secwatch.observer/filing/0000784199-24-000234.json
- Plain text: https://secwatch.observer/filing/0000784199-24-000234.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.